Johnson & Johnson $JNJ Shares Sold by Argent Capital Management LLC

Key Points

• Argent Capital Management reduced its Johnson & Johnson holdings by 5.5% in the third quarter, selling 4,046 shares and retaining 69,933 shares valued at approximately $18.5 million. Institutional investors own 69.55% of JNJ.
• Analysts remain broadly positive, with Johnson & Johnson receiving a “Moderate Buy” consensus rating and an average price target of $275.87; recent targets range from $278 to $305.
• JNJ reported quarterly earnings and revenue above expectations, while maintaining a quarterly dividend of $1.34 per share, equivalent to a 2.1% yield. The stock recently traded at $254.04, down 0.8%.

Argent Capital Management LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 69,933 shares of the company's stock after selling 4,046 shares during the quarter. Argent Capital Management LLC's holdings in Johnson & Johnson were worth $18,514,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in JNJ. Outlook Capital Management LLC bought a new stake in Johnson & Johnson during the 2nd quarter worth about $28,000. Matrix Trust Co raised its position in shares of Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after acquiring an additional 54 shares during the last quarter. Montgomery Financial Services LLC acquired a new position in shares of Johnson & Johnson during the second quarter valued at $43,000. Hyposwiss Advisors SA bought a new position in Johnson & Johnson in the fourth quarter valued at about $42,000. Finally, Polaris Financial Partners bought a new position in Johnson & Johnson in the third quarter valued at about $56,000. Institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

A number of research firms have issued reports on JNJ. JPMorgan Chase & Co. upped their target price on shares of Johnson & Johnson from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Tuesday, September 29th. Royal Bank Of Canada boosted their price target on shares of Johnson & Johnson from $265.00 to $287.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. Scotiabank restated an "outperform" rating and issued a $305.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Johnson Rice reaffirmed a "buy" rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. Finally, Bank of America reiterated a "neutral" rating and set a $278.00 target price on shares of Johnson & Johnson in a research report on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average price target of $275.87.

Johnson & Johnson Trading Down 0.8%

Johnson & Johnson stock traded down $1.99 during midday trading on Monday, hitting $254.04. 3,653,098 shares of the stock were exchanged, compared to its average volume of 7,972,831. The stock has a market capitalization of $612.20 billion, a PE ratio of 29.44, a P/E/G ratio of 2.52 and a beta of 0.21. The company has a fifty day simple moving average of $266.37 and a two-hundred day simple moving average of $248.40. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52 week low of $182.94 and a 52 week high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same period last year, the business posted $2.77 earnings per share. The business's revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts anticipate that Johnson & Johnson will post 11.54 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a dividend of $1.34 per share. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson's payout ratio is currently 62.11%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares of the company's stock, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the company's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company's stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 87,569 shares of company stock valued at $23,064,544 in the last three months. Insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.